HSBC on Infosys
Downgrade to hold, TP cut to Rs 1110 from Rs 1340
INFY cut its FY27 growth guidance; while it was well anticipated quantum was higher than consensus expectation
Co announced Ashiss Kumar Dash (internal leader) as new CEO, taking over from 1 April 2027
Relative valuations are inexpensive, but near-term quarters are likely to remain weak
JPM on Infosys
Downgrade to neutral, TP Rs 1050
1Q print missed sharply on revenues and revenue guidance was cut sharply for second time in a row after a sharp miss in 4Q.
Growth momentum has now taken multiple hits including weak demand, rising AI deflation (sometimes mid-contract) in addition to contract challenges at Daimler and an Energy, Utilities Resources Services (EURS) contract termination
New organic guide at -0.2 to 1.3% (1.5-3% overall) points to a sharp slowdown YY that depends on sustaining a 0.4-1.4% CQGR in a tough environment
While signings have been strong, AI deflation means revenue conversion remains soft.
Margins were largely in line and need some effort in defence over rest of year.
Infosys has also announced a CEO transition to company lifer Ashiss Kumar Dash (head of EURS) over next nine months, which could pave way for a smoother transition vs. historical leadership changes.
CITI on Infosys
Neutral. TP Rs 1065
Weak 1Q - flattish organic revenues qoq; margins & deal TCV were decent.
Forward looking indicators –
(a) Guidance now factors the Optimum Health acquisition – on an organic basis, mid-point of guidance lowered by 170+ bps;
(b) TTM TCV +30% yoy;
(c) Headcount ~1% yoy;
(d) Mgmt commentary – Uncertain macro; caution on discretionary spends; high competitive intensity. Infosys announced Ashiss Kumar Dash (Global head – EURS) as CEO designate
Factor in acquisition; FY27E/FY28E EPS revised lower by 1-2%
CLSA on Infosys
O-P, TP Rs 1109
1QFY27 revenue growth and FY27 guidance cut were disappointing, but Ebit margin did beat & order book was steady.
One of key concerns around lack of management’s aggression amid AI disruption was addressed to an extent with appointment of Mr Ashiss Kumar Dash as CEO-designate, & as CEO from 1 Apr 2027
In his current role, he is heading EURS vertical & has been with INFY for last 31 years.
This is first time in INFY’s 45-year history an insider & non-founder has been empowered with this role
INFY has been known to have a highly meritocratic culture, reflected in several of its ex-employees appointed as CEOs of several Indian/global SIs
Nomura on Infosys
Buy, TP Rs 1290
1QFY27 – revenue surprises negatively led by client-specific issue
FY27E organic growth guidance cut by 170bp at mid-point
Margin guidance for FY27E unchanged at 20-22%
Smooth CEO transition remains a key monitorable
Infy is currently trading at an attractive valuation of 13x FY28F EPS of Rs80.4
@Reematendulkar@CNBCTV18Live
@connectgurmeet As of now, India is an anti- AI play. FPIs will have no choice but to return to our market after all the initial hype surrounding AI is done. India will quickly innovate and ramp up when the value chain trickles down to the AI application and IT infrastructure layer.
Smallcaps Quietly Outperforming in a Weak Market 🔥🔥
✅Bookmark it
Jain Resources
Data Patterns
Khazanchi Jewellers
TD Power
Advait Energy
Precision Wires
GNG Electronics
Anand Rathi Wealth
CCL Products
Acutaas
SMS Pharma
KNR Heat Exchange
Belrise
Kwality Pharma
CP Plus
KSH
Titan Biotech
These are the kind of names quietly holding their ground while the broader market shakes.
Which stocks are you finding attractive right now ❓
✅ RETWEET if you found this useful
Follow @TheAlpha10X for more such insights
See the COMMENT section for early ENTRY & EXIT. 👇👇👇👇
🔥Some SMEs looking good on guidance for FY26 ( >1000cr Marketcap)
Save It For Later 🔖
1. OrianaPower - 2000 - 2500 Cr. topline FY26
2. RajeshPower - 1600 - 1700cr topline
3. Afcom - 80-100% PAT growthE
4. KPGEL - 50-60% topline conservative
5. Aimtron - 280cr topline FY26
6. KrishnaDefence - 30-40% CAGR minimum for next 3yrs
7. AlpexSolar - 100% Topline FY26E
8. AustralianPremium - 75% CAGR next 2yrs
9. INA Insolation - 3000cr topline/350cr bottomline FY26
10. CosmicCRF - Double volume FY26
11. Danish - 50% topline expected
12. Vilas - 65% topline growth
13. ConcordControl - 40% for next 2/3yrs
Which One Do You Have?
Comment 👇 Retweet For Friends
Disclaimer:- do your due diligence before investing ...I have no course no telegram ...only study purpose study !!
Valuations across most listed hospital players
Focus on EV/EBITDA on FY27E⏬
Industry bed capacity itself is expected to grow at ~13% CAGR between FY26-29, with several players expanding even faster through greenfield additions & acquisitions
src : Equirus